津药达仁堂集团股份有限公司 独立董事关于公司2023年第五次董事会相关事项的 独立意见 根据中国证监会《关于在上市公司建立独立董事制度的指导意 见》、《上市公司治理准则》，上海证券交易所《股票上市规则》、 本公司《公司章程》与《独立董事制度》等有关规定，我们作为津药 达仁堂集团股份有限公司（以下简称"本公司"或"公司"）的独立 董事，对公司2023年第五次董事会审议的相关事项进行了核查，现对 有关事项发表独立意见如下： 一、关于2023年半年度募集资金存放与实际使用情况的专项报告 公司2023年半年度募集资金的存放与实际使用情况符合中国证 监会、上海证券交易所及公司《募集资金管理办法》的相关规定，不 存在违规使用募集资金的行为，不存在改变或变相改变募集资金投向 和损害股东利益的情况。公司编制的《募集资金存放与实际使用情况 的专项报告》真实反映了公司募集资金存放、使用、管理情况，公司 已披露的募集资金存放、使用等相关信息及时、真实、准确、完整， 不存在虚假记载、误导性陈述和重大遗漏，符合中国证监会、上海证 券交易所关于上市公司募集资金管理的有关规定。 二、《关于继续使用部分闲置募集资金暂时补充公司流动资金的 议 ...

津药达仁堂集团股份有限公司对天津 医药集团财务有限公司的风险持续评估报告 按照《上海证券交易所上市公司自律监管指引第 5 号 —交易与关联交易》的要求，津药达仁堂集团股份有限公 司（以下简称"公司"）通过查验天津医药集团财务有限 公司（以下简称"财务公司"）的《营业执照》与《金融 许可证》等证件资料，并审阅了包括资产负债表、利润表、 现金流量表等在内的财务公司的定期财务报告，对其经营 资质、业务和风险状况进行了评估，现将有关风险评估具 体情况报告如下： 一、天津医药集团财务有限公司基本情况 财务公司经原中国银行保险业监督管理委员会批准， 于 2016 年 9 月正式成立，由天津市医药集团有限公司、津 药达仁堂集团股份有限公司、天津力生制药股份有限公司、 天津药业集团有限公司和天津金益投资担保有限责任公司 共同出资，注册资本金 5 亿元人民币。 注册地址：天津自贸试验区（空港经济区）西四道 168 号融和广场 3-2-501、502；3-3-501 法定代表人：幸建华 金融许可证机构编码：L0248H212000001 统一社会信用代码：91120118MA05L0R67F 财务公司经营范围： 吸收成员单位存款 ...

表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、审议通过了公司 2023 年半年度《募集资金存放与实际使用 情况的专项报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 证券代码：600329 证券简称：达仁堂 编号：临 2023-032 号 津药达仁堂集团股份有限公司 2023 年第四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2023 年 8 月 4 日发出会议通知，并于 2023 年 8 月 14 日 以现场结合通讯方式召开了 2023 年第四次监事会会议，会议应到监 事 3 名，实到监事 3 名。本次会议召开符合公司章程的有关规定，经 与会监事认真审议，形成如下决议： 一、审核公司 2023 年半年度报告无误，并发表审核意见如下： 1．公司 2023 年半年度报告的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定； 2．公司 2023 年半年度报告的内容和格式符合中国证监会和证券 交易所的各项规定，所包含的信息从各个方面真实地反映出公司当期 的经营 ...

津药达仁堂集团股份有限公司将于 2023 年 8 月 14 日以现场结合 通讯方式召开了 2023 年第五次董事会会议。会议将审议"聘任公司 2023 年度审计机构的议案"。 根据中国证监会《关于在上市公司建立独立董事制度的指导意 见》、《上市公司治理准则》，上海证券交易所《股票上市规则》和新 加坡交易所有关规则、本公司《公司章程》与《独立董事制度》等相 关规定，作为公司独立董事，我们在事前对本次事项进行认真研究， 基于独立判断的立场，发表如下意见： 津药达仁堂集团股份有限公司 关于公司 2023 年第五次董事会相关事项的 独立董事事前认可意见 中审华会计师事务所（特殊普通合伙）具备证券、期货相关业务 执业资格，具备为上市公司提供审计服务的经验与能力，能够满足公 司 2023 年度境内财务报告审计及内部控制审计工作的要求。胡官陈 有限责任合伙会计师事务所（FKT）是由中审华会计师事务所（特殊 普通合伙）推荐的境外审计机构，两家审计机构具备良好地合作关系， 有利于确保境内外审计工作高效完成。胡官陈有限责任合伙会计师事 务所（FKT）能够满足公司 2023 年度境外财务报告的审计工作。我 们同意将聘任中审华会计师 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-031 号 津药达仁堂集团股份有限公司 2023 年第五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司于 2023 年 8 月 4 日发出会议通知， 并于 2023 年 8 月 14 日以现场结合通讯方式召开了 2023 年第五次董 事会会议。本次会议应参加董事 9 人，实参加董事 9 人。会议召开符 合《公司法》、《证券法》和《公司章程》有关召开董事会会议的规定。 会议形成如下决议： 一、审议通过了公司 2023 年中国准则半年度报告全文、摘要以 及国际准则的中期报告。 据本公司董事会全体成员及管理层所知，没有任何其他信息将致 使该报告不确实或具有误导性。 表决结果：同意 9 票，反对 0 票，弃权 0 票 二、审议通过了公司 2023 年半年度《募集资金存放与实际使用 情况的专项报告》。（详见临时公告 2023-033 号） 四、审议通过了公司继续使用不超过 5 亿元人民币自有资金进行 现金管理的议案。 1 公司于 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-034 号 津药达仁堂集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2015年8月26日，公司2015年第八次董事会及2015年第五次监事会审议通过 了《关于使用部分闲置募集资金暂时补充公司流动资金的议案》，公司使用部分 闲置募集资金2.5亿元补充公司流动资金，使用期限自批准之日起不超过12个月。 1 2016年8月23日，公司已将上述用于暂时补充流动资金的募集资金全部归还至募 集资金专户。 2016年8月24日，公司2016年第七次董事会及2016年第五次监事会审议通过 了《关于继续使用部分闲置募集资金暂时补充公司流动资金的议案》，公司使用 部分闲置募集资金2.5亿元补充公司流动资金，使用期限自批准之日起不超过12 个月。2017年8月22日，公司已将上述用于暂时补充流动资金的募集资金全部归 还至募集资金专户。 2017年8月23日，公司2017年第七次董事会及2017年第四次监事会审议通过 了《 ...

津药达仁堂集团股份有限公司（以下简称"公司"）2022 年第 四次董事会审议通过了《关于继续使用部分闲置募集资金暂时补充公 司流动资金的议案》，同意公司使用部分闲置募集资金 4 亿元补充公 司流动资金，使用期限自董事会批准之日起不超过 12 个月，到期将 归还至公司募集资金专户。相关具体内容详见 2022 年 8 月 15 日在《中 国证券报》、《上海证券报》及上海证券交易所网站（www.sse.com.cn） 上刊登的《关于使用部分闲置募集资金暂时补充流动资金的公告》 （临时公告 2022-026 号）。 截至 2023 年 8 月 10 日，公司已将上述用于暂时补充流动资金的 募集资金全部归还至募集资金专户，并已将上述募集资金的归还情况 通知了保荐机构及保荐代表人。 特此公告。 津药达仁堂集团股份有限公司董事会 2023 年 8 月 11 日 证券代码：600329 证券简称：达仁堂 编号：临 2023-030 号 津药达仁堂集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金 到期归还的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-022 号 津药达仁堂集团股份有限公司 关于召开业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 津药达仁堂集团股份有限公司（以下简称"公司"）已分别于 2023 年 4 月 1 日、2023 年 4 月 29 日发布了 2022 年年度报告与 2023 年第一季度报告（详见上海证券交易所网站 www.sse.com.cn）。为便 于广大投资者更深入全面地了解公司经营业绩等情况，公司定于2023 年 5 月 30 日（星期二）下午 15:00—16:00 举行"业绩说明会"（以下 简称"说明会"）。 二、说明会召开时间、地点 召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 召开地点：东方财富路演 1 会议召开时间：2023 年 5 月 30 日（星期二）下午 15:00—16:00 会议召开地点：东方财富路演 （https://roadshow.eastmoney.com/luyan/4 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,154,405,776.85, representing a year-on-year increase of 14.03%[4] - Net profit attributable to shareholders was RMB 400,788,396.53, showing a significant increase of 100.79% compared to the same period last year[4] - Basic and diluted earnings per share both stood at RMB 0.52, marking a 100% increase year-on-year[4] - Total operating revenue for Q1 2023 reached ¥2,154,405,776.85, an increase of 14.05% compared to ¥1,889,294,355.26 in Q1 2022[16] - Net profit for Q1 2023 was ¥397,782,701.63, compared to ¥202,246,413.81 in Q1 2022, representing a growth of 96.59%[18] - Earnings per share for Q1 2023 were ¥0.52, doubling from ¥0.26 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥397,884,789.40, compared to ¥201,906,275.33 in Q1 2022, reflecting an increase of 97.00%[18] Cash Flow - The net cash flow from operating activities reached RMB 186,966,594.00, reflecting a year-on-year growth of 137.21%[4] - Cash inflow from operating activities for Q1 2023 was approximately ¥2.21 billion, an increase of 24% compared to ¥1.78 billion in Q1 2022[20] - Net cash flow from operating activities reached ¥186.97 million in Q1 2023, up from ¥78.82 million in Q1 2022, representing a growth of 137%[20] - Total cash inflow from investment activities was ¥116.36 million in Q1 2023, a decrease of 73% from ¥435.31 million in Q1 2022[21] - Net cash flow from financing activities was ¥323.50 million in Q1 2023, compared to a net outflow of ¥17.52 million in Q1 2022[21] - The net increase in cash and cash equivalents for Q1 2023 was approximately ¥582.34 million, compared to an increase of ¥411.10 million in Q1 2022[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,866,527,859.66, up 6.99% from the end of the previous year[5] - The total liabilities have increased to RMB 3,560,725,598.61 from RMB 3,333,434,867.96, suggesting a rise in financial obligations[14] - The company's total liabilities increased to ¥3,933,820,819.32 in Q1 2023 from ¥3,605,028,900.58 in Q1 2022, marking a rise of 9.09%[17] - The total equity attributable to shareholders reached ¥6,905,220,131.40 in Q1 2023, up from ¥6,521,460,534.99 in Q1 2022, an increase of 5.88%[17] Expenses - Sales expenses rose by 39% primarily due to the increase in sales revenue[9] - Financial expenses increased by 64%, mainly attributed to higher interest costs[9] - Research and development expenses for Q1 2023 were ¥24,195,352.76, compared to ¥19,332,928.57 in Q1 2022, indicating a rise of 25.31%[17] - Cash paid to employees in Q1 2023 was ¥243.44 million, an increase of 22% from ¥199.52 million in Q1 2022[20] - Cash paid for taxes in Q1 2023 was ¥229.69 million, significantly higher than ¥98.40 million in Q1 2022, indicating a growth of 133%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,433, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, accounting for 42.811% of the total[10] Other Income - The company reported a 655% increase in other income, mainly from government subsidies received[9] - The company reported a financial income of ¥12,287,594.48 in Q1 2023, down from ¥13,078,314.45 in Q1 2022[17] Current Assets - As of March 31, 2023, the company's total current assets amount to RMB 7,903,764,059.62, an increase from RMB 7,245,444,756.23 in the previous year[13] - The company's cash and cash equivalents stand at RMB 3,455,307,279.55, compared to RMB 2,882,523,954.61 as of December 31, 2022, reflecting a significant increase[13] - Accounts receivable have risen to RMB 2,440,287,659.57 from RMB 2,146,213,416.31 year-over-year, indicating a growth in sales or credit terms[13] Financial Management - The company reported a decrease in accounts payable, which fell to RMB 686,731,735.62 from RMB 724,326,434.25, indicating improved cash flow management[14] - The company has a significant increase in short-term borrowings, which rose to RMB 351,276,795.73 from RMB 101,638,515.28[14] Intangible Assets - The company has maintained a stable level of intangible assets, which increased to RMB 332,127,671.68 from RMB 281,127,790.71[14] Product Development - The company has not disclosed any significant new product developments or market expansion strategies in the current report[12]

Financial Performance - The company achieved a net profit of ¥861,793,906.84 in 2022, representing a 12.05% increase compared to ¥769,144,377.12 in 2021[21]. - Total operating revenue for 2022 was ¥8,249,249,565.18, marking a 19.42% increase from ¥6,907,544,256.00 in 2021[21]. - The basic earnings per share rose to ¥1.12 in 2022, a 12.00% increase from ¥1.00 in 2021[23]. - The weighted average return on equity improved to 13.15% in 2022, up from 12.64% in 2021[23]. - The company reported a net profit of ¥769,227,070.99 after deducting non-recurring gains and losses, a 3.94% increase from ¥740,056,524.95 in 2021[21]. - The net profit attributable to shareholders for the fourth quarter was CNY 132,833,170.58, with a total annual net profit of CNY 1,061,793,007.84, reflecting a decrease compared to the previous year[26]. - The company achieved a total revenue of CNY 8,249,249,565.18 in 2022, representing a year-on-year increase of 19.42% compared to CNY 6,907,544,256.00 in the previous year[66]. - The net profit attributable to the parent company for 2022 was CNY 86,179,390.00, with total assets amounting to CNY 1,015,698,200.00 and net assets of CNY 655,195,310.00[64]. Cash Flow and Investments - Cash flow from operating activities decreased by 20.55% to ¥677,245,078.23 in 2022, down from ¥852,401,231.63 in 2021[21]. - The net cash flow from operating activities in the fourth quarter was CNY 550,771,466.60, significantly higher than the previous quarters[26]. - The company reported a net cash flow from investing activities of -12.28 million RMB, a significant improvement of 96.06% compared to the previous period[84]. - The company increased its long-term equity investments to CNY 760.19 million by the end of 2022, up from CNY 729.66 million at the beginning of the year[121]. - The company invested CNY 45 million in acquiring Tianjin Darentang Jingzhong Traditional Chinese Medicine, achieving 100% ownership[122]. Research and Development - In 2022, the company invested CNY 151 million in R&D, enhancing the quality standards of major products and improving drug safety and treatment experience[42]. - The company’s R&D investment accounted for 1.83% of its operating revenue, with a capitalized proportion of 4.17%[114]. - The R&D investment for the Qingfei Xiaoyan Wan major product's secondary development was CNY 107.15 million, reflecting a year-on-year increase of 108.4%[115]. - The company is actively developing two generic drugs for consistency evaluation, aiming to improve market competitiveness[107]. - The company has a total of 402 patents, including 256 invention patents, supporting its innovation and product development capabilities[62]. Market Strategy and Expansion - The company implemented a "1+5" strategic layout focusing on brand leadership and five related industries, including traditional Chinese medicine and health products[34]. - The company aims to enhance the competitiveness of the "Darentang" brand and has initiated trademark registrations and subsidiary name changes to support this strategy[34]. - The company plans to explore a combined medical and health model that incorporates traditional Chinese medicine, enhancing its service offerings[34]. - The company is focusing on the integration of traditional Chinese medicine resources and the establishment of a national chain of "Darentang" pharmacies[34]. - The company plans to expand its market presence and invest in new product development to sustain growth in the coming years[71]. Operational Efficiency - The company has established a marketing network covering the medical market, retail market, third terminal, and online channels, achieving steady progress in operational targets[44]. - The company has integrated its sales platforms, including the establishment of the commercial sales division in 2022 to operate generic drug products[38]. - The company streamlined its management structure, reducing the number of departments from 14 to 12 to better meet strategic development needs[40]. - The company is focused on optimizing smart manufacturing processes to reduce costs and improve quality, implementing lean management principles and enhancing production efficiency[140]. - The company has established a centralized procurement management system for medicinal materials, focusing on cost reduction, quality assurance, and supply stability[48]. Corporate Governance and Management - The company operates under a robust governance structure, having listings in both Singapore and Shanghai, which enhances its capital operation and financing capabilities[63]. - The company has a board of directors consisting of 8 members, with 4 independent directors[158]. - The company’s board of directors is responsible for determining the remuneration of directors and supervisors, authorized by the shareholders' meeting[167]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[175]. - The company has a clear cash dividend policy that aligns with regulatory requirements and shareholder interests[184]. Social Responsibility and Compliance - The company is committed to social responsibility and compliance, focusing on employee welfare, environmental protection, and ESG initiatives as part of its operational strategy[144]. - The company invested CNY 10.81 million in environmental protection during the reporting period[196]. - The company has strengthened its internal control system, adding 6 new regulations in 2022[192]. - The company is required to ensure compliance with new regulations regarding traditional Chinese medicine by July 2023, which mandates the submission of safety information for re-registration[148]. - The company is committed to fostering a high-performance culture by optimizing its human resource management system and implementing performance evaluation mechanisms[40]. Risks and Challenges - The company faces risks related to policy changes in the pharmaceutical industry, including the impact of centralized procurement and pricing reforms, which may introduce market uncertainties[145]. - The company is also exposed to cost pressures from rising raw material prices and labor costs, which could affect profitability and operational stability[145]. - The medical and OTC market profitability may decline due to increased buyer power represented by medical insurance payments and intensified competition within the industry[146]. - The company faces potential risks in new drug development, including failures, delays in market entry, and slow growth post-launch due to strict regulatory approvals and market conditions[147]. - The regulatory environment for drug quality has intensified since the implementation of the Drug Administration Law in December 2019, increasing the responsibility of drug marketing authorization holders[148].